A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Phase 3
630
about 6.6 years
18+
33 sites in CA, CO, CT +17
About this study
Researchers are testing whether sonrotoclax plus obinutuzumab or sonrotoclax plus rituximab are more effective than venetoclax plus rituximab in treating adults with relapsed and/or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The trial will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Obinutuzumab
- 2.Take Rituximab
- 3.Take Sonrotoclax
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
obinutuzumab, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), bcl-2 inhibitor, venetoclax
injection, intravenous, infusion, oral
Primary: Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm D
Secondary: Change from Baseline in EORTC QLQ for Chronic Lymphocytic Leukemia (EORTC QLQ-CLL17) Symptom Burden and Fatigue Scales, Change from Baseline in the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Global Health Status/Quality of Life and Physical Functioning Scales, Complete Response Rate as assessed by BIRC for Arm A versus Arm D, Duration of Response (DOR) per BIRC and by INV, Number of Participants with Treatment-Emergent Adverse Events (TEAEs), OS for Arm A versus Arm B, OS for Arm B versus Arm D, OS for Arm C versus Arm D
Oncology